Palmitoylethanolamide (PEA) as a potential therapeutic agent in Alzheimer's disease
S Beggiato, MC Tomasini, L Ferraro - Frontiers in pharmacology, 2019 - frontiersin.org
… In the present review, we summarized the current preclinical and clinical evidence of PEA
as a possible therapeutic agent in Alzheimer’s disease. The possible PEA neuroprotective …
as a possible therapeutic agent in Alzheimer’s disease. The possible PEA neuroprotective …
Palmitoylethanolamide controls reactive gliosis and exerts neuroprotective functions in a rat model of Alzheimer's disease
… activities of systemic administration of PEA in adult male rats … the effects induced by PEA, we
co-administered PEA with the … : novel therapeutic strategies in Alzheimer's disease? Trends …
co-administered PEA with the … : novel therapeutic strategies in Alzheimer's disease? Trends …
Neuroglial roots of neurodegenerative diseases: therapeutic potential of palmitoylethanolamide in models of Alzheimer's disease
C Scuderi, L Steardo - CNS & Neurological Disorders-Drug …, 2013 - ingentaconnect.com
… Along this line palmitoylethanolamide (PEA) has attracted much attention … of PEA in rat
neuronal cultures and organotypic hippocampal slices challenged with Aβ, and treated with PEA …
neuronal cultures and organotypic hippocampal slices challenged with Aβ, and treated with PEA …
Palmitoylethanolamide protects against the amyloid-β25-35-induced learning and memory impairment in mice, an experimental model of Alzheimer disease
G D'agostino, R Russo, C Avagliano… - …, 2012 - nature.com
… Considering the anti-inflammatory properties of PEA, and the existence of a PEA/PPAR-α
signaling at CNS level, we hypothesized that PEA may exert neuroprotective effect in an …
signaling at CNS level, we hypothesized that PEA may exert neuroprotective effect in an …
… palmitoylethanolamide rescues learning and memory impairments in a triple transgenic mouse model of Alzheimer's disease by exerting anti-inflammatory and …
… palmitoylethanolamide (PEA) demonstrates exceptional potential as a novel treatment for
AD. We have previously demonstrated PEA … the effects of chronic PEA administration on the …
AD. We have previously demonstrated PEA … the effects of chronic PEA administration on the …
Neuroprotection by association of palmitoylethanolamide with luteolin in experimental Alzheimer's disease models: the control of neuroinflammation
I Paterniti, M Cordaro, M Campolo… - … Disorders-Drug …, 2014 - ingentaconnect.com
… an important role in neuroinflammatory disorders and in AD … compound such as
palmitoylethanolamide (PEA) and the well … in Alzheimer's disease. Ann Neurol 1997; 41(1): 17-24. …
palmitoylethanolamide (PEA) and the well … in Alzheimer's disease. Ann Neurol 1997; 41(1): 17-24. …
Palmitoylethanolamide dampens reactive astrogliosis and improves neuronal trophic support in a triple transgenic model of Alzheimer's disease: in vitro and in vivo …
MR Bronzuoli, R Facchinetti… - … medicine and …, 2018 - Wiley Online Library
… in the FC at an early stage of the disease. Moreover, we demonstrate for the first time that
acute PEA in vitro, as well as chronic um-PEA in vivo, may counteract such phenomenon, …
acute PEA in vitro, as well as chronic um-PEA in vivo, may counteract such phenomenon, …
Palmitoylethanolamide counteracts enteric inflammation and bowel motor dysfunctions in a mouse model of Alzheimer's disease
V D'Antongiovanni, C Pellegrini, L Antonioli… - Frontiers in …, 2021 - frontiersin.org
… Alzheimer’s disease (AD) are lacking. This study was designed to investigate the beneficial
effect of PEA … In addition, the ability of PEA in modulating the activation of enteric glial cells (…
effect of PEA … In addition, the ability of PEA in modulating the activation of enteric glial cells (…
Palmitoylethanolamide in CNS health and disease
GM Raso, R Russo, A Calignano, R Meli - Pharmacological Research, 2014 - Elsevier
… Among AEs, palmitoylethanolamide (PEA) is … of PEA have been mainly related to the
reduction of neuronal firing and to control of inflammation. Growing evidence suggest that PEA may …
reduction of neuronal firing and to control of inflammation. Growing evidence suggest that PEA may …
Chronic oral palmitoylethanolamide administration rescues cognitive deficit and reduces neuroinflammation, oxidative stress, and glutamate levels in a transgenic …
S Beggiato, MC Tomasini, T Cassano… - Journal of Clinical …, 2020 - mdpi.com
… N-palmitoylethanolamide (PEA) is a lipid mediator belonging to the class of the N-acylethanolamine.
Products containing PEA, also in ultramicronized formulation (um-PEA), … that PEA, …
Products containing PEA, also in ultramicronized formulation (um-PEA), … that PEA, …
相关搜索
- alzheimer's disease mouse model
- potential therapeutic agent in alzheimer's disease
- experimental model of alzheimer disease
- transgenic murine model of alzheimer's disease
- early stage of alzheimer's disease
- rat model of alzheimer's disease
- alzheimer's disease alternative targets
- alzheimer's disease ultramicronized palmitoylethanolamide
- alzheimer's disease neuronal trophic support
- amyloid β25 alzheimer disease
- impairment in mice alzheimer disease
- alzheimer's disease neuroprotective functions
- alzheimer's disease reactive astrogliosis
- alzheimer's disease reactive gliosis
- alzheimer's disease cognitive deficit
- alzheimer's disease oxidative stress